Artemis Investment Management LLP trimmed its holdings in shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) by 9.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,073,591 shares of the company’s stock after selling 116,593 shares during the period. Artemis Investment Management LLP owned 5.95% of BioXcel Therapeutics worth $15,508,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of BTAI. Rational Advisors LLC bought a new position in shares of BioXcel Therapeutics during the third quarter worth about $48,000. Strs Ohio grew its position in shares of BioXcel Therapeutics by 431.3% during the third quarter. Strs Ohio now owns 8,500 shares of the company’s stock worth $59,000 after acquiring an additional 6,900 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new position in shares of BioXcel Therapeutics during the second quarter worth about $138,000. Bank of New York Mellon Corp bought a new position in shares of BioXcel Therapeutics during the second quarter worth about $198,000. Finally, Squarepoint Ops LLC grew its position in shares of BioXcel Therapeutics by 10.5% during the third quarter. Squarepoint Ops LLC now owns 35,548 shares of the company’s stock worth $250,000 after acquiring an additional 3,386 shares during the last quarter. 23.19% of the stock is currently owned by institutional investors.

Several equities analysts have recently commented on BTAI shares. Canaccord Genuity upped their price target on shares of BioXcel Therapeutics from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 31st. HC Wainwright restated a “buy” rating and set a $30.00 price target (up previously from $25.00) on shares of BioXcel Therapeutics in a research report on Wednesday, January 8th. ValuEngine lowered shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, December 16th. BMO Capital Markets set a $21.00 price target on shares of BioXcel Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Finally, SunTrust Banks started coverage on shares of BioXcel Therapeutics in a research report on Tuesday, November 12th. They set a “buy” rating and a $24.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $22.80.

Shares of BTAI opened at $15.30 on Wednesday. The firm has a 50-day moving average price of $9.81 and a 200 day moving average price of $8.64. The firm has a market capitalization of $256.82 million, a PE ratio of -11.59 and a beta of 3.77. The company has a quick ratio of 5.04, a current ratio of 5.04 and a debt-to-equity ratio of 0.03. BioXcel Therapeutics Inc has a 52-week low of $3.76 and a 52-week high of $19.89.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its earnings results on Thursday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.02. On average, equities analysts expect that BioXcel Therapeutics Inc will post -2.26 EPS for the current year.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Read More: Recession

Institutional Ownership by Quarter for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.